EndocrinologyEvidence For A New Genetic Link To Therapeutic Efficacy For Alzheimer's Disease
Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, today announced further evidence for genetic interactions impacting the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in Alzheimer"s disease. New data from the company"s previously completed double-blind, placebo-controlled trial in patients with mild-to-moderate Alzheimer"s disease demonstrates an interaction between two genetic markers that strongly influence the therapeutic response in patients. Dr. Samuel Henderson, Executive Director of Research, will present these results at the 2009 International Conference on Alzheimer"s Disease (ICAD) sponsored by the Alzheimer"s Association.
During this study, patients received daily administration of either AC-1202 or placebo for 90 days, with efficacy assessments performed at Baseline (Day 0), Day 45, Day 90 and after a two week washout from their assigned product on Day 104. In addition, analyses of a number of genotypic markers judged to be relevant to the physiological background of Alzheimer"s disease were also performed.
Previous analysis of the study revealed that patients administered AC-1202 who lacked the epsilon 4 variant of the APOE gene (E4(-)), demonstrated significant improvement from baseline values in the Alzheimer"s Disease Assessment Scale-Cognitive (ADAS-Cog) and improvement compared to placebo of 4.77 at Day 45 and 3.36 at Day 90 (p About Axona(TM)
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer"s disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer"s disease by providing an alternative energy for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer"s disease therapies.
About Alzheimer"s Disease
Alzheimer"s disease, the most common form of dementia, is a progressive and fatal disease for which there is no cure. In the United States, 5.2 million people are living with AD, and it has become the sixth leading cause of death. The disease attacks the brain"s cells, resulting in loss of memory, executive function and language skills.
AD significantly impacts millions of family members and other caregivers - mentally, physically and financially. The national Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week. With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.
About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer"s disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer"s disease. Accera engages in research, development and commercialization of other clinical applications for Axona.
Accera, Inc.